Seed Capital, one of Denmark’s most established early-stage venture capital firms, has closed its fifth fund, Seed Capital Fund V, at € 130 million. With this new fund, Seed Capital is expanding its focus beyond Denmark to back 15–17 seed-stage companies across the Nordics in FinTech, Cybersecurity and Resilience, and AI-driven B2B solutions.
For over 20 years, Seed Capital has been a pioneer in backing Danish founders. Now, with Fund V, the firm is leveraging its expertise and fund model to support high-potential startups across the Nordic region. The fund’s investment thesis centers on three key verticals:
- Reinventing financial infrastructure (FinTech)
- Enhancing cybersecurity and resilience
- Transforming SMBs and enterprises (AI-driven B2B)
“Broadening into the Nordics is a natural move for us and it’s been important for us to get the right team, with strong expertise and global mindset. Together with Geeta Schmidt and Lars Andersen, we have formed a partner team with both company building and venture growth expertise, with the goal of scaling them globally. This is also reflected in what we’re looking for in the founders we back, founders building global winners”
said Christian Broendum, Managing Partner at Seed Capital
Strong LP Support and Early Investments
Seed Capital’s Fund V is backed by a diverse group of limited partners (LPs), including Realdania, EIFO, Dansk Vækst Kapital, Sampension, Lauritzen Fonden, Augustinus Fonden, family offices, and angel investors.
“Seed has been one of the cornerstones of the Danish venture ecosystem for more than 20 years, helping build and scale many of Denmark’s most successful technology companies. With a new generation of partners, a proven platform, and fresh capital, Seed is well positioned to continue backing the most ambitious founders and strengthening the Danish and Nordic startup ecosystem,”
said Alexander Knudsen, investor at EIFO
The fund has already made its first investments, including Norlix, Blackbird Coffee, Fortiv, Moxso, Pluto Markets, Repodo, and Oplane, with more to come.